Media

TRIANNI Signs Agreement with Stanford University for Use of The Trianni Mouse in Vaccine Research

San Francisco, CA, USA., February 22, 2017 –Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement […]

Continue reading

TRIANNI Signs Licensing Agreement for Transgenic Mouse Platform Use with Janssen

San Francisco, CA, USA., February 15, 2017 –Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement […]

Continue reading

TRIANNI is BioWorld’s Partner in Focus

TRIANNI is featured in BioWorld Today as a Partner in Focus. Read the feature here. The feature highlights: • Advantages […]

Continue reading

Transgenic Mice: Transforming Targeted Monoclonal Antibody (mAb) Therapeutics

Download Full Whitepaper Monoclonal antibodies (mAbs) currently represent the largest class of biopharmaceutical products. Market growth is projected to climb […]

Continue reading

Biopharma Dealmakers feature The Trianni Mouse Platform

Biopharma Dealmakers from the publishers of Nature, feature TRIANNI, Inc’s Trianni Mouse platform for the discovery of monoclonal antibodies. Read […]

Continue reading

TRIANNI Announces Issuance of Patent in China

San Francisco, CA, USA., June 9, 2016 – Trianni, Inc. is pleased to announce that a patent for the Trianni […]

Continue reading

Nature Magazine Profiles TRIANNI

Download Full Feature |   In just a few short years, California-based  TRIANNI Inc. has emerged as one of the […]

Continue reading

TRIANNI Announces Partnering Agreement with Evotec

San Francisco, CA, USA., May 17, 2016 – Trianni, Inc. (“TRIANNI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: […]

Continue reading

TRIANNI and LakePharma Announce Strategic Technology Partnering Agreement

San Francisco and Belmont, CA, USA, {May 9, 2016} – Trianni, Inc., (TRIANNI)  a private biotech company developing novel antibody […]

Continue reading

TRIANNI Announces Issuance of Russian Federation Patent

SAN FRANCISCO, March 2, 2016 — Trianni, Inc. (TRIANNI) announces that key aspects of its human antibody mouse platform were issued […]

Continue reading